Nektar Therapeutics

NASDAQ:NKTR   4:00:00 PM EDT
2.88
+0.08 (+2.86%)
: $2.88 0.00 (0.00%)
Products

Nektar And Collaborators Announce Publication In Blood Advances Of Preclinical Data Demonstrating NKTR-255, A Novel Polymer-Conjugated Human IL-15

Published: 11/09/2022 14:47 GMT
Nektar Therapeutics (NKTR) - Nektar and Collaborators Announce Publication in Blood Advances of Preclinical Data Demonstrating Nktr-255, a Novel Polymer-conjugated Human Il-15, Improves Efficacy of Cd19-targeted Car-t Cell Immunotherapy.
Nektar Therapeutics - Polymer-conjugated Il-15 (nktr-255) Induced Cd8(+) T Cell and Natural Killer Cell Proliferation in Vivo.
Nektar Therapeutics - Nktr-255 Enhanced Efficacy of Human Cd19 Car-t Cells in a Xenogeneic Lymphoma Model.